Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-532P is a pseudogene associated with the U6 small nuclear RNA family. The canonical U6 snRNA is a highly conserved and essential small nuclear RNA that plays a critical role in the spliceosome, the molecular complex responsible for removing introns from pre-mRNA during RNA splicing[5][7]. Pseudogenes such as RNU6-532P represent non-functional segments of DNA arising from duplication or retrotransposition events; they typically are not transcribed or translated into functional products. While some pseudogenes in other families can exhibit regulatory effects — such as acting as “miRNA decoys” or competitive endogenous RNAs (ceRNAs) — there is no evidence or documentation of RNU6-532P having such functions[4][1]. Pseudogenes are common in eukaryotic genomes and rarely participate directly in cellular processes. In summary, RNU6-532P is a non-functional pseudogene of the U6 snRNA family with no therapeutic, biomarker, or mechanistic relevance to human disease or pharmacology[1][5].
None. There are no mechanisms of action for drugs targeting this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 532, pseudogene (RNU6-532P).